Swiss Primary Biliary Cholangitis Cohort
Swiss Primary Biliary Cholangitis Cohort Study
This project will collect medical information and yearly blood samples from adults in Switzerland with primary biliary cholangitis to help understand its course and outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fondazione Epatocentro Ticino Academic / other |
| Locations | 13 sites (Lugano, Canton Ticino and 12 other locations) |
| Trial ID | NCT03146910 on ClinicalTrials.gov |
What this trial studies
The cohort enrolls adults diagnosed with PBC and plans an initial visit plus at least one annual follow-up to collect clinical data and medical history. Whole blood is taken once a year for a centralized biobank and, when available from routine care, liver tissue samples may be included. Existing medical records and coded data are also used to build high-quality prospective datasets on epidemiology, natural history, treatment response and outcomes. The platform is intended to support future scientific projects and collaborations with international PBC reference networks.
Who should consider this trial
Good fit: Adults (18 or older) living in Switzerland with a diagnosis of primary biliary cholangitis—or with isolated anti-mitochondrial antibodies or PBC-specific anti-nuclear antibodies—are eligible.
Not a fit: People under 18, those living outside Switzerland, or patients hoping for an immediate therapeutic benefit are unlikely to gain direct clinical benefit from participating.
Why it matters
Potential benefit: If successful, the cohort could improve understanding of PBC disease course and treatment responses, enabling better care and new research opportunities for patients.
How similar studies have performed: Other national and international PBC cohorts have successfully generated valuable epidemiological and natural history data, so this project builds on established observational approaches.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * diagnose of Primary biliary cholangitis (according to EASL Clinical Practice Guidelines: management of cholestatic liver diseases). * Subjects with isolated anti-mitochondrial antibodies and/or isolated PBC-specific anti-nuclear antibodies are also included * Patients/subjects aged at least 18 years and living in Switzerland are included Exclusion Criteria: * N/A
Where this trial is running
Lugano, Canton Ticino and 12 other locations
- Fondazione Epatocentro Ticino — Lugano, Canton Ticino, Switzerland (Recruiting)
- Gastroenterologie und Hepatologie, Clarunis - Universitäres Bauchzentrum Basel — Basel, Switzerland (Recruiting)
- Inselspital — Bern, Switzerland (Recruiting)
- Spital Bülach — Bülach, Switzerland (Recruiting)
- Kantonsspital Graubünden — Chur, Switzerland (Recruiting)
- Hôpitaux Universitaires de Genève, Service de Gastroentérologie & Hépatologie, Département des Spécialités — Geneva, Switzerland (Recruiting)
- CHUV: Centre hospitalier universitaire vaudois — Lausanne, Switzerland (Recruiting)
- Kantonsspital Baselland — Liestal, Switzerland (Recruiting)
- Luzerner Kantonsspital — Lucerne, Switzerland (Recruiting)
- EOC Ospedale Regionale di Lugano - Italiano — Lugano, Switzerland (Recruiting)
- Kantonsspital St.Gallen — Sankt Gallen, Switzerland (Recruiting)
- Kantonsspital Winterthur — Winterthur, Switzerland (Recruiting)
- Universitätsspital Zürich — Zurich, Switzerland (Recruiting)
Study contacts
- Study coordinator: Andreas Cerny, Prof. Dr. med
- Email: andreas.cerny@hin.ch
- Phone: +41919106570
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.